A Phase 3 interventional study of GSK573719/GW642444 125/25 and GSK573719/GW642444 62.5/25 in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 53 sites in 7 countries. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-02-15.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, none of them phase 3. GSK573719 · Pulmonary Disease, Chronic Obstructive.
Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, this one is the 17th largest by enrollment, is one of 8 that started in 2011, is one of 14 in phase 3, and was the 10th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
By country, each count listing its studies:
GSK573719: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 307 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 131 across the 43 interventional studies. Of the 37 that completed or were terminated, 25 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 43 have an industry lead sponsor. The 9 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline: 7 open now, 8 under way, 5 of them phase 3. Of 264 finished, 141 (53%) have results posted.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 75th largest by enrollment of the 236 interventional ones that give a count, is one of 26 that started in 2011, is one of 65 in phase 3, and was the 113th registered.
GlaxoSmithKline’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2000.
2 of the studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07133880University of Tennessee Graduate School of MedicineCompare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators | 2026-12-01 |
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 276 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI).
Expiratory airflow limitation is the most obvious physiological change associated with chronic obstructive pulmonary disease (COPD). A consequence of airflow limitation is gas trapping as expiration becomes flow limited. This may occur at rest with more severe airway obstruction and is most evident during exercise as lung emptying is reduced and increased ventilation does not allow full expiration. This increased gas trapping or hyperinflation is the cause of much of the increased work of breathing, dyspnea, and exercise intolerance in subjects with COPD (O'Donnell 1997; O'Donnell, 1993). Spirometric measurement of airflow limitation, particularly as assessed by forced expiratory volume in one second (FEV1), is commonly used for the diagnosis of and assessment of response to pharmacotherapeutic intervention in COPD. However, changes in FEV1 may not fully predict symptomatic responses and alternative measures of lung hyperinflation such as exercise tolerance and exertional dyspnea may be more sensitive to therapeutic intervention and/or more clinically relevant than FEV1 [O'Donnell1999; Bauerle, 1998; O'Donnell, 1998; Officer, 1998]. GSK573719/GW642444 Inhalation Powder, a combination of the long-acting muscarinic antagonist (LAMA) bronchodilator GSK573719 and the long-acting beta2-agonist (LABA) bronchodilator GW642444, is in development for the maintenance treatment of airflow obstruction associated with COPD. Development of this product is supported by studies showing improvement in lung function with similar safety when use of combinations of long-acting bronchodilators with different mechanisms of action are compared with single bronchodilator therapy [van Noord 2005; van Noord van Noord 2006; Tashkin 2008]. Previous studies have demonstrated that treatment with short- and long-acting bronchodilators including ipratropium, tiotropium, and salmeterol reduces resting lung hyperinflation as measured by functional residual capacity (FRC), residual volume (RV), and inspiratory capacity (IC), with associated improvements in exercise endurance time and exertional dyspnoea in subjects with COPD [Ayers, 2001; O'Donnell 1998; O'Donnell 2004; Pepin 2005; Pepin 2007; Ramirez-Venegas 1997]. However, the effect of combined LAMA/LABA therapy on these measures is not well characterized.
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI) Approximately 312 subjects with moderate/severe chronic obstructive pulmonary disease (COPD) will be randomised in order to achieve 208 subjects completing both treatment periods of 3 months.. There will be a total of 12 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 12 to 21 day run-in period followed by two 12-week treatment periods that are separated by a 14 day wash-out. Clinic visits will be conducted at Screening (Visit 1), twice during the run-in period (Visits 2 and 3), at randomization (Visit 4) and three times during the first treatment period, on Treatment Day 2 (Visit 5) and at 6 and 12 weeks (Visits 6 and 7 respectively). During the washout period of 14 days there will be 2 clinic visits (Visits 8 and 9). During the second treatment period there will be 3 clinic visits, on Treatment Day 2 (Visit 10) and at 6 and 12 weeks (Visits 11 and 12 respectively). A Safety Follow-Up assessment (Visit 13) to record adverse events will be conducted by telephone 7 days after the end of the second treatment period or early withdrawal. Efficacy measurements will include pre and post dose FEV1, lung volume measurements and exercise endurance time measured using the endurance shuttle walking test (ESWT). Safety and tolerability will be assessed by collection of adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), clinical laboratory tests and incidence of COPD exacerbations. Dyspnea will be assessed using the Exercise Dyspnea Scale (EDS), a patient-reported outcome. Blood samples will also be collected for potential pharmacogenetics analysis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
125mcg/25mcg nDPI
Drug: GSK573719 125 · Drug: GW642444 25 · Device: placebo
62.5mcg/25mcg nDPI
Drug: GSK573719 62.5 · Drug: GW642444 25 · Device: placebo
125mcg nDPI
Drug: GSK573719/GW642444 125/25 · Device: placebo
62.5mcg nDPI
Drug: GSK573719/GW642444 62.5/25 · Device: placebo
25mcg nDPI
Drug: GSK573719/GW642444 125/25 · Drug: GSK573719/GW642444 62.5/25 · Device: placebo
Plb nDPI
Drug: GSK573719/GW642444 125/25 · Drug: GSK573719/GW642444 62.5/25 · Drug: GSK573719 125 · Drug: GSK573719 62.5 · Drug: GW642444 25
125mcg/ 25mcg QID (Once daily , inhaled)
62.5mcg/25mcg QID
125mcg QID
62.5mcg QID
25mcg QID
Comparator QID
Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period
Exercise endurance time (EET) post-dose at Week 12 is defined as the EET obtained 3 hours after dosing at Week 12. EET was measured using the externally paced field walking test called the endurance shuttle walk test (ESWT). Analysis performed using a repeated measures model with covariates of period walking speed, mean walking speed, period, treatment, visit, smoking status, center group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. The model used all available 3-hour post-dose change from baseline EET values recorded on Day 2, Week 6 and Week 12. Baseline was the EET assessment obtained prior to dosing on Day 1 of each period. The mean walking speed for each participant is the mean of the levels used for the ESWT in each of the two treatment periods. The period walking speed for each participant and treatment period is the difference between the level for that participant and period and the mean walking speed for that participant.
Time frame: Week 12 of each treatment period (up to Study Week 30)
Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 24 hours after dosing on Treatment Day 84. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions.
Time frame: Week 12 of each treatment period (up to Study Week 30)
Change From Baseline in Inspiratory Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
Inspiratory capacity (IC) is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Baseline is the IC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough IC is measured pre-dose on Treatment Week 12 of each treatment period. IC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12 of each treatment period. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. IC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.
Time frame: Week 12 of each treatment period (up to Study Week 30)
Change From Baseline in Functional Residual Capacity (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
Functional Residual Capacity (FRC) is defined as the amount of air still left in the lungs after breathing out normally. Baseline is the FRC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough FRC is measured pre-dose on Treatment Week 12. FRC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. FRC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.
Time frame: Week 12 of each treatment period (up to Study Week 30)
Change From Baseline in Residual Volume (Trough and 3-hours Post-dose) at Week 12 of Each Treatment Period
Residual Volume (RV) is defined as the air that remains in the lungs after breathing out as fully as possible. Baseline is the RV value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough RV is measured pre-dose on Treatment Week 12. RV 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. RV measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 1.
Time frame: Week 12 of each treatment period (up to Study Week 30)
Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period
FEVI is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit post-dose FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 3 hours after dosing on Treatment Day 85. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions 3 hour post-dose FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12.
Time frame: Week 12 of each treatment period (up to Study Week 30)
Participants (par.) who were eligible completed a 12- to 21-day Run-in Period followed by two 12-week treatment (trt) periods.
| Milestone | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC 125/25 µg QD |
|---|---|---|---|---|---|---|
| Started | 84 | 22 | 24 | 36 | 71 | 70 |
| Completed | 65 | 21 | 19 | 31 | 61 | 61 |
| Not completed | 19 | 1 | 5 | 5 | 10 | 9 |
| Withdrew: Adverse event | 6 | 1 | 1 | 3 | 3 | 4 |
| Withdrew: Lack of efficacy | 6 | 0 | 2 | 0 | 1 | 3 |
| Withdrew: Protocol violation | 2 | 0 | 1 | 1 | 1 | 2 |
| Withdrew: Met protocol-defined stopping criteria | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 | 1 | 1 | 3 | 0 |
| Milestone | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC 125/25 µg QD |
|---|---|---|---|---|---|---|
| Started | 65 | 21 | 19 | 31 | 61 | 61 |
| Completed | 65 | 21 | 18 | 28 | 58 | 59 |
| Not completed | 0 | 0 | 1 | 3 | 3 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 3 | 2 | 2 |
| Milestone | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC 125/25 µg QD |
|---|---|---|---|---|---|---|
| Started | 67 | 18 | 17 | 28 | 59 | 58 |
| Completed | 55 | 17 | 14 | 25 | 55 | 51 |
| Not completed | 12 | 1 | 3 | 3 | 4 | 7 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Lack of efficacy | 9 | 0 | 2 | 2 | 1 | 3 |
| Withdrew: Study closed/terminated | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 0 | 2 | 0 |
Exercise endurance time (EET) post-dose at Week 12 is defined as the EET obtained 3 hours after dosing at Week 12. EET was measured using the externally paced field walking test called the endurance shuttle walk test (ESWT). Analysis performed using a repeated measures model with covariates of period walking speed, mean walking speed, period, treatment, visit, smoking status, center group, visit by period walking speed, visit by mean walking speed and visit by treatment interactions. The model used all available 3-hour post-dose change from baseline EET values recorded on Day 2, Week 6 and Week 12. Baseline was the EET assessment obtained prior to dosing on Day 1 of each period. The mean walking speed for each participant is the mean of the levels used for the ESWT in each of the two treatment periods. The period walking speed for each participant and treatment period is the difference between the level for that participant and period and the mean walking speed for that participant.
| Seconds | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC/VI 125/25 µg QD |
|---|---|---|---|---|---|---|
| Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period | 0.1 ± 16.66 | 25.1 ± 30.18 | 74.8 ± 31.58 | 30.7 ± 24.79 | 69.5 ± 17.09 | 65.9 ± 17.48 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit trough (pre-bronchodilator and pre-dose) FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 24 hours after dosing on Treatment Day 84. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions.
| Liters | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC/VI 125/25 µg QD |
|---|---|---|---|---|---|---|
| Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 12 of Each Treatment Period | -0.043 ± 0.0156 | 0.101 ± 0.0267 | 0.212 ± 0.0287 | 0.069 ± 0.0222 | 0.200 ± 0.0156 | 0.218 ± 0.0159 |
Inspiratory capacity (IC) is defined as the maximum amount of air that can be inhaled into the lungs from the normal resting position after breathing out normally. Baseline is the IC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough IC is measured pre-dose on Treatment Week 12 of each treatment period. IC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12 of each treatment period. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. IC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.
| Liters | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC/VI 125/25 µg QD |
|---|---|---|---|---|---|---|
| Trough | -0.021 ± 0.0271 | 0.077 ± 0.0471 | 0.216 ± 0.0505 | 0.081 ± 0.0391 | 0.216 ± 0.0274 | 0.204 ± 0.0281 |
| 3-hours post-dose | -0.021 ± 0.0273 | 0.155 ± 0.0465 | 0.208 ± 0.0498 | 0.156 ± 0.0389 | 0.295 ± 0.0276 | 0.312 ± 0.0283 |
Functional Residual Capacity (FRC) is defined as the amount of air still left in the lungs after breathing out normally. Baseline is the FRC value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough FRC is measured pre-dose on Treatment Week 12. FRC 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. FRC measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 12.
| Liters | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC/VI 125/25 µg QD |
|---|---|---|---|---|---|---|
| Trough | -0.083 ± 0.0460 | -0.200 ± 0.0804 | -0.263 ± 0.0862 | -0.218 ± 0.0666 | -0.434 ± 0.0469 | -0.333 ± 0.0480 |
| 3-hours post-dose | -0.094 ± 0.0461 | -0.315 ± 0.0786 | -0.405 ± 0.0836 | -0.431 ± 0.0654 | -0.616 ± 0.0471 | -0.503 ± 0.0480 |
Residual Volume (RV) is defined as the air that remains in the lungs after breathing out as fully as possible. Baseline is the RV value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Trough RV is measured pre-dose on Treatment Week 12. RV 3-hours post-dose is measured from the value obtained 3 hours after dosing on Treatment Week 12. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions. RV measurements were taken electronically by plethysmography on Day 2, Week 6 and Week 1.
| Liters | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC/VI 125/25 µg QD |
|---|---|---|---|---|---|---|
| Trough | -0.049 ± 0.0491 | -0.266 ± 0.0847 | -0.289 ± 0.0909 | -0.291 ± 0.0705 | -0.516 ± 0.0500 | -0.421 ± 0.0511 |
| 3-hours post-dose | -0.071 ± 0.0495 | -0.451 ± 0.0855 | -0.534 ± 0.0911 | -0.483 ± 0.0711 | -0.714 ± 0.0505 | -0.566 ± 0.0516 |
FEVI is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Baseline is the FEV1 value recorded pre-dose on Day 1 of each treatment period, mean Baseline is the mean of the Baselines for each participant, and period Baseline is the difference between the Baseline and the mean Baseline in each treatment period for each participant. Clinic visit post-dose FEV1 at Week 12 (Treatment Day 85) is defined as the FEV1 value obtained 3 hours after dosing on Treatment Day 85. Analysis performed using a repeated measures model with covariates of period Baseline, mean Baseline, period, treatment, visit, smoking status, center group, visit by period Baseline, visit by mean Baseline and visit by treatment interactions 3 hour post-dose FEV1 measurements were taken electronically by spirometry on Day 2, Week 6 and Week 12.
| Liters | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC/VI 125/25 µg QD |
|---|---|---|---|---|---|---|
| Change From Baseline in 3-hours Post-dose FEV1 at Week 12 of Each Treatment Period | -0.019 ± 0.0175 | 0.168 ± 0.0296 | 0.215 ± 0.0317 | 0.143 ± 0.0246 | 0.297 ± 0.0175 | 0.343 ± 0.0179 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs), defined as those events occuring while participants were on treatment up until one day after the last dose (up to Week 33), are reported.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 4/151 (2.6%) | 31/151 (20.5%) |
| UMEC 62.5 µg QD | — | 1/40 (2.5%) | 5/40 (12.5%) |
| UMEC 125 µg QD | — | 1/41 (2.4%) | 14/41 (34.1%) |
| VI 25 µg QD | — | 2/64 (3.1%) | 12/64 (18.8%) |
| UMEC/VI 62.5/25 µg QD | — | 3/130 (2.3%) | 20/130 (15.4%) |
| UMEC/VI 125/25 µg QD | — | 5/128 (3.9%) | 18/128 (14.1%) |
| Event | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC/VI 125/25 µg QD |
|---|---|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/151 | 1/40 | 0/41 | 0/64 | 0/130 | 0/128 |
| Deep vein thrombosisVascular disorders | 0/151 | 1/40 | 0/41 | 0/64 | 0/130 | 0/128 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/151 | 0/40 | 1/41 | 0/64 | 0/130 | 0/128 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/151 | 0/40 | 0/41 | 1/64 | 0/130 | 0/128 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/151 | 0/40 | 0/41 | 0/64 | 0/130 | 2/128 |
| Leukocytoclastic vasculitisSkin and subcutaneous tissue disorders | 0/151 | 0/40 | 0/41 | 1/64 | 0/130 | 0/128 |
| CellulitisInfections and infestations | 0/151 | 0/40 | 0/41 | 0/64 | 0/130 | 1/128 |
| Subcutaneous abscessInfections and infestations | 0/151 | 0/40 | 0/41 | 0/64 | 0/130 | 1/128 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/151 | 0/40 | 0/41 | 0/64 | 0/130 | 1/128 |
| Chest painGeneral disorders | 0/151 | 0/40 | 0/41 | 0/64 | 0/130 | 1/128 |
| Event | Placebo | UMEC 62.5 µg QD | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 62.5/25 µg QD | UMEC/VI 125/25 µg QD |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 10/151 | 4/40 | 4/41 | 1/64 | 8/130 | 2/128 |
| HeadacheRespiratory, thoracic and mediastinal disorders | 8/151 | 1/40 | 4/41 | 1/64 | 3/130 | 6/128 |
| SinusitisInfections and infestations | 3/151 | 0/40 | 2/41 | 3/64 | 2/130 | 0/128 |
| ToothacheGastrointestinal disorders | 1/151 | 0/40 | 2/41 | 0/64 | 1/130 | 0/128 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/151 | 1/40 | 1/41 | 0/64 | 6/130 | 0/128 |
| DyspnoeaGastrointestinal disorders | 6/151 | 0/40 | 1/41 | 1/64 | 0/130 | 1/128 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/151 | 0/40 | 1/41 | 2/64 | 2/130 | 5/128 |
| Back painMusculoskeletal and connective tissue disorders | 5/151 | 0/40 | 1/41 | 2/64 | 0/130 | 2/128 |
| Upper respiratory tract infectionInfections and infestations | 1/151 | 0/40 | 0/41 | 2/64 | 3/130 | 3/128 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/151 | 0/40 | 1/41 | 2/64 | 0/130 | 0/128 |
| Age, Continuous(Years) | All Study Treatments |
|---|---|
| Mean | 62.6 ± 7.88 |
| Sex: Female, Male(Participants) | All Study Treatments |
|---|---|
| Female | 139 |
| Male | 168 |
| Race/Ethnicity, Customized(Participants) | All Study Treatments |
|---|---|
| African American/African Heritage | 6 |
| American Indian or Alaska Native | 1 |
| Asian - South East Asian Heritage | 1 |
| White - White/Caucasian/European Heritage | 298 |
| Mixed Race | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Mar 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 9 months after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: GSK573719 · Vilanterol
Pulmonary Disease, Chronic Obstructive →